Lactobacillus reuteri DSM 17938 Improves Feeding Intolerance in Preterm Infants
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Feeding tolerance is extremely important in preterm infants. This study aimed to evaluate whether preterm infants receiving Lactobacillus reuteri DSM 17938 would develop fewer symptoms of feeding intolerance. Secondary outcomes were duration of parenteral nutrition, time to reach full feeding, length of hospital stay, sepsis, necrotizing enterocolitis (NEC), diarrhea, and mortality. Methods: This double-blind randomized controlled trial of L. reuteri DSM 17938 versus placebo included 94 neonates with a gestational age of 28–34 weeks and birth weight of 1,000–1,800 g. Results: Feeding intolerance (vomiting and/or distension) was less common in the probiotic group than in the placebo group (8.5% vs. 25.5%; relative risk, 0.33; 95% confidence interval, 0.12–0.96; p=0.03). No significant intergroup differences were found in proven sepsis, time to reach full feeding, length of hospital stay, or diarrhea. The prevalence of NEC (stages 2 and 3) was 6.4% in the placebo group vs. 0% in the probiotic group (relative risk, 1.07; 95% confidence interval, 0.99–1.15; p=0.24). Mortality rates were 2.1% in the probiotic group and 8.5% in the placebo group, p=0.36). Conclusion: The administration of L. reuteri DSM 17938 to preterm infants was safe and significantly reduced feeding intolerance. No significant differences were found in any other secondary outcomes.
Abstract
Purpose: Feeding tolerance is extremely important in preterm infants. This study aimed to evaluate whether preterm infants receiving Lactobacillus reuteri DSM 17938 would develop fewer symptoms of feeding intolerance. Secondary outcomes were duration of parenteral nutrition, time to reach full feeding, length of hospital stay, sepsis, necrotizing enterocolitis (NEC), diarrhea, and mortality. Methods: This double-blind randomized controlled trial of L. reuteri DSM 17938 versus placebo included 94 neonates with a gestational age of 28–34 weeks and birth weight of 1,000–1,800 g. Results: Feeding intolerance (vomiting and/or distension) was less common in the probiotic group than in the placebo group (8.5% vs. 25.5%; relative risk, 0.33; 95% confidence interval, 0.12–0.96; p=0.03). No significant intergroup differences were found in proven sepsis, time to reach full feeding, length of hospital stay, or diarrhea. The prevalence of NEC (stages 2 and 3) was 6.4% in the placebo group vs. 0% in the probiotic group (relative risk, 1.07; 95% confidence interval, 0.99–1.15; p=0.24). Mortality rates were 2.1% in the probiotic group and 8.5% in the placebo group, p=0.36). Conclusion: The administration of L. reuteri DSM 17938 to preterm infants was safe and significantly reduced feeding intolerance. No significant differences were found in any other secondary outcomes.
참고문헌 (34)
- de Vrese M, "Probiotics, prebiotics, and synbiotics", Adv Biochem Eng Biotechnol, 111, pp.1~66 (2008)
- Sinkiewicz G, "Occurrence of Lactobacillus reuteri in human breast milk", Microb Ecol Health Dis, 20, pp.112~116 (2008)
- Thomas DW, "Hepatology, and Nutrition. Probiotics and prebiotics in pediatrics", Pediatrics, 126, pp.1217~1231 (2010)
- Pietzak M, "Bacterial colonization of the neonatal gut", J Pediatr Gastroenterol Nutr, 38, pp.389~391 (2004)
- Reuter G, "The Lactobacillus and Bifidobacterium microflora of the human intestine : composition and succession", Curr Issues Intest Microbiol, 2, pp.43~53 (2001)
- Huda S, "Neonatal necrotizing enterocolitis : clinical challenges, pathophysiology and management", Pathophysiology, 21, pp.3~12 (2014)
- Lin HC, "Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants : a multicenter, randomized, controlled trial", Pediatrics, 122, pp.693~700 (2008)
- Wu SF, "Necrotizing enterocolitis : old problem with new hope", Pediatr Neonatol, 53, pp.158~163 (2012)
- Chu A, "Necrotizing enterocolitis predictive markers and preventive strategies", Neoreviews, 14, pp.e113~20 (2013)
- Shadkam MN, "Effects of probiotic Lactobacillus reuteri(DSM 17938)on the incidence of necrotizing enterocolitis in very low birth weight premature infants", Iran J Neonatol, 6, pp.15~20 (2015)
- Athalye-Jape G, "Lactobacillus reuteri DSM 17938 as a probiotic for preterm neonates : a strain-specific systematic review", JPEN J Parenter Enteral Nutr, 40, pp.783~794 (2016)
- Rojas MA, "Prophylactic probiotics to prevent death and nosocomial infection in preterm infants", Pediatrics, 130, pp.e1113~20 (2012)
- Indrio F, "The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns", J Pediatr, 152, pp.801~806 (2008)
- Rao SC, "Probiotic supplementation and lateonset sepsis in preterm infants : a meta-analysis", Pediatrics, 137, pp.e20153684~ (2016)
- Oncel MY, "Lactobacillus reuteri for the prevention of necrotising enterocolitis in very low birthweight infants : a randomised controlled trial", Arch Dis Child Fetal Neonatal Ed, 99, pp.F110~115 (2014)
- AlFaleh K, "Probiotics for prevention of necrotizing enterocolitis in preterm infants", Cochrane Database Syst Rev, (4), pp.CD005496~ (2014)
- Hunter C, "Effect of routine probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight <1000 grams : a sequential analysis", BMC Pediatr, 12, pp.142~ (2012)
- 이장훈, "An update on necrotizing enterocolitis: pathogenesis and preventive strategies", Clinical and Experimental Pediatrics, 54(9), pp.368~372 (2011), 대한소아청소년과학회
- Doron S, "Risk and safety of probiotics", Clin Infect Dis, 60(Suppl 2), pp.S129~134 (2015)
- Vahabnezhad E, "Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis", J Clin Gastroenterol, 47, pp.437~439 (2013)
- Kaban RK, "Analisis dampak perbedaan pajanan konsentrasi oksigen awal pada resusitasi bayi prematur terhadap displasia bronkopulmonal, integritas mukosa, dan mikrobiota usus", pp.2016
- Sjarif DR, "Panduan berbasis bukti: asuhan nutrisi untuk bayi prematur", Departemen Ilmu Kesehatan Anak FKUI-RSCM, ~ (2016)
- Khashana A, "Incidence of feeding intolerance in preterm neonates in neonatal intensive care units, Port Said, Egypt", J Clin Neonatol, 5, pp.230~232 (2016)
- Dominguez KM, "Necrotizing enterocolitis", Clin Perinatol, 39, pp.387~401 (2012)
- Christensen RD, "Necrotizing enterocolitis in term infants", Clin Perinatol, 40, pp.69~78 (2013)
- Wejryd E, "Probiotics promoted head growth in extremely low birthweight infants in a double-blind placebo-controlled trial", Acta Paediatr, 108, pp.62~69 (2019)
- Schanler RJ, "Human milk is the feeding strategy to prevent necrotizing enterocolitis", Curr Pediatr Rep, 2, pp.264~268 (2014)
- van den Akker CHP, "Prebiotics & Committee on Nutrition Probiotics for preterm infants: a strainspecific systematic review and network meta-analysis", J Pediatr Gastroenterol Nutr, 67, pp.103~122 (2018)
- Wang Q, "Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very low-birth-weight infants : an updated meta-analysis of 20 randomized, controlled trials", J Pediatr Surg, 47, pp.241~248 (2012)
- Escribano E, "Increased incidence of necrotizing enterocolitis associated with routine administration of Infloran™ in extremely preterm infants", Benef Microbes, 9, pp.683~690 (2018)
- Romeo MG, "Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns : incidence of late-onset sepsis and neurological outcome", J Perinatol, 31, pp.63~69 (2011)
- Ofek Shlomai N, "Probiotics for preterm neonates: what will it take to change clinical practice?", Neonatology, 105, pp.64~70 (2014)
- Indrio F, "Probiotic supplementation in preterm : feeding intolerance and hospital cost", Nutrients, 9, pp.E965~ (2017)
- Pabst O, "Secretory IgA in the coordination of establishment and maintenance of the microbiota", Trends Immunol, 37, pp.287~296 (2016)